Modus Therapeutics Holding AB (MODTX) - Total Assets
Based on the latest financial reports, Modus Therapeutics Holding AB (MODTX) holds total assets worth Skr12.69 Million SEK (≈ $1.37 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See MODTX net asset quality index to measure how much of total assets are equity-financed.
Modus Therapeutics Holding AB - Total Assets Trend (2018–2025)
This chart illustrates how Modus Therapeutics Holding AB's total assets have evolved over time, based on quarterly financial data. Check MODTX intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Modus Therapeutics Holding AB - Asset Composition Analysis
Current Asset Composition (December 2025)
Modus Therapeutics Holding AB's total assets of Skr12.69 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 89.7% |
| Accounts Receivable | Skr1.31 Million | 10.4% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr0.00 | 0.0% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Modus Therapeutics Holding AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Modus Therapeutics Holding AB market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Modus Therapeutics Holding AB's current assets represent 100.0% of total assets in 2025, an increase from 99.9% in 2018.
- Cash Position: Cash and equivalents constituted 89.7% of total assets in 2025, down from 97.5% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 10.4% of total assets.
Modus Therapeutics Holding AB Competitors by Total Assets
Key competitors of Modus Therapeutics Holding AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $763.95 Million |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
|
China | CN¥4.48 Billion |
|
Novavax Inc
NASDAQ:NVAX
|
USA | $1.04 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Modus Therapeutics Holding AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.51 | 1.76 | 7.04 |
| Quick Ratio | 3.51 | 1.76 | 7.38 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr9.07 Million | Skr2.08 Million | Skr5.57 Million |
Modus Therapeutics Holding AB - Advanced Valuation Insights
This section examines the relationship between Modus Therapeutics Holding AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.69 |
| Latest Market Cap to Assets Ratio | 0.60 |
| Asset Growth Rate (YoY) | 159.7% |
| Total Assets | Skr12.69 Million |
| Market Capitalization | $7.64 Million USD |
Valuation Analysis
Below Book Valuation: The market values Modus Therapeutics Holding AB's assets below their book value (0.60x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Modus Therapeutics Holding AB's assets grew by 159.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Modus Therapeutics Holding AB (2018–2025)
The table below shows the annual total assets of Modus Therapeutics Holding AB from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr12.69 Million ≈ $1.37 Million |
+159.75% |
| 2024-12-31 | Skr4.88 Million ≈ $525.60K |
-75.63% |
| 2023-12-31 | Skr20.04 Million ≈ $2.16 Million |
+77.81% |
| 2022-12-31 | Skr11.27 Million ≈ $1.21 Million |
-46.81% |
| 2021-12-31 | Skr21.19 Million ≈ $2.28 Million |
+182.89% |
| 2020-12-31 | Skr7.49 Million ≈ $806.15K |
+265.24% |
| 2019-12-31 | Skr2.05 Million ≈ $220.72K |
-95.63% |
| 2018-12-31 | Skr46.95 Million ≈ $5.05 Million |
-- |
About Modus Therapeutics Holding AB
Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. It develops Sevuparin, a lipopolysaccharide in Phase IIa trial to treat patients with sepsis, septic shock, anemia associated with chronic kidney disease, endotoxemia, severe malaria, and other diseases involving severe systemic inflammation. Modus Therapeutics Holding AB (pu… Read more